Pronunciation: en ti’ vee oh
Generic name: vedolizumab [ VE-doe-LIZ-ue-mab ]
Dosage form: intravenous infusion, subcutaneous injection
Drug class: Selective immunosuppressants

Medically reviewed by Melisa Puckey, BPharm. Last updated on Jul 17, 2025.

What is Entyvio?

Entyvio is used for active ulcerative colitis (UC) and Crohn's disease to improve symptoms, help achieve remission, and decrease the use of steroid medications. Entyvio is a selective immunosuppressant that works by blocking white blood cells from entering your GI tract (intestine), which improves symptoms and does not usually lead to systemic immunosuppression.

Entyvio can be given as a subcutaneous injection for maintenance treatment using Entyvio Pens or prefilled syringes, or can be administered as an intravenous infusion for both induction and maintenance treatment.

Entyvio FDA approval is for the treatment of adults with moderate to severe active ulcerative colitis (UC) or Crohn's disease. No biosimilars of vedolizumab have been approved by the FDA.

Entyvio (vedolizumab) belongs to the drug class called integrin receptor antagonists. It may also be called a monoclonal antibody or a selective immunosuppressant. 

Entyvio’s mechanism of action is by binding to α4β7 integrin on the surface of a type of white blood cell called memory T-lymphocytes. Binding to α4β7 integrin blocks it from interacting with MAdCAM-1 (mucosal addressin cell adhesion molecule-1). This interaction plays a key role in causing the chronic inflammation seen in people with IBD.

Entyvio side effects

Common side effects of Entyvio

The most common side effects of Entyvio include:

• fever, sore throat, flu symptoms;
• cold symptoms such as stuffy nose, sinus pain, sneezing;
• cough with mucus, shortness of breath, chest discomfort;
• pain in your arms or legs;
• tiredness;
• headache, joint pain, back pain;
• rash, itching; or nausea.

Serious Entyvio side effects

Infusion-Related Reactions and Hypersensitivity Reactions. Get emergency medical help if you have signs of an allergic reaction to this medicine: hives, difficulty breathing, swelling of your face, lips, tongue, or throat.

Some Entyvio side effects may occur during the injection. Tell your caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.

Progressive Multifocal Leukoencephalopathy (PML) Entyvio may cause a serious brain infection that can lead to disability or death. Call your doctor right away if you have problems with speech, thought, vision, or muscle movement. These symptoms may start gradually and get worse quickly.

This medicine may cause other serious side effects. Call your doctor at once if you have:

• fever, chills, body aches, cold or flu symptoms, mouth and throat ulcers, skin sores;
• pain, warmth, swelling, or oozing around your anal area;
• nausea, vomiting, severe diarrhea, diarrhea that is watery or bloody, stomach cramps, weight loss;
• cough, pain when swallowing; or
• liver problems - nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Related/similar drugs

Warnings

Entyvio can cause serious side effects on your brain or liver, and may cause a serious infection. Call your doctor right away if you have a fever, tiredness, muscle aches, sore throat, shortness of breath, skin sores, painful urination, loss of appetite, upper stomach pain, dark urine, yellowing of your skin and eyes, or problems with speech, thought, vision, or muscle movement.

Tell your caregivers if you have any reactions during the injection, such as dizziness, nausea, itching, headache, chest tightness, trouble breathing, or swelling in your face.

Do not receive a "live" vaccine while using Entyvio.

Before taking this medicine

You should not use Entyvio if you are allergic to the active ingredient vedolizumab or any of the inactive ingredients.

To make sure Entyvio is safe for you, tell your doctor if you have ever had:

• an active or recent infection;
• liver disease;
• signs of infection such as fever, cough, or flu symptoms;
• if you are scheduled to receive any vaccines.

Tell your doctor if you have ever had tuberculosis or if anyone in your household has tuberculosis. Also, tell your doctor if you have recently traveled. Tuberculosis and some fungal infections are more common in certain parts of the world, and you may have been exposed during travel.

You should be up to date with all needed vaccinations before receiving Entyvio.

Pregnancy

Tell your doctor if you are pregnant or plan to become pregnant. Having active ulcerative colitis or Crohn's disease symptoms during pregnancy may increase the risk of premature birth or low birth weight. The benefit of treating these conditions may outweigh any risks to the baby.

If you use Entyvio while you are pregnant, make sure any doctor caring for your new baby knows that you used the medicine during pregnancy. Being exposed to vedolizumab in the womb could affect your baby's vaccination schedule during the first few months of life.

If you are pregnant, your name may be listed on a pregnancy registry to track the effects of vedolizumab on the baby.

Breastfeeding

Tell your doctor if you are breastfeeding or plan to breastfeed. Entyvio passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take this medicine. 

Warnings

Entyvio infusion and pen can cause serious side effects on your brain or liver, and may cause a serious infection. Call your doctor right away if you have a fever, tiredness, muscle aches, sore throat, shortness of breath, skin sores, painful urination, loss of appetite, upper stomach pain, dark urine, yellowing of your skin and eyes, or problems with speech, thought, vision, or muscle movement.

Tell your caregivers if you have any reactions during the injection, such as dizziness, nausea, itching, headache, chest tightness, trouble breathing, or swelling in your face.

Before starting this medication, you should be up to date with all immunizations. While patients are receiving Entyvio, they may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks. There are no data on the secondary transmission of infection by live vaccines in patients receiving Entyvio.

Before taking this medicine

You should not use this medicine if you are allergic to the active ingredient vedolizumab or any of the inactive ingredients.

To make sure this medicine is safe for you, tell your doctor if you have ever had:

• an active or recent infection;
• liver disease;
• signs of infection such as fever, cough, or flu symptoms;
• if you are scheduled to receive any vaccines.

Tell your doctor if you have ever had tuberculosis or if anyone in your household has tuberculosis. Also, tell your doctor if you have recently traveled. Tuberculosis and some fungal infections are more common in certain parts of the world, and you may have been exposed during travel.

You should be up to date with all needed vaccinations before receiving this medicine.

Pregnancy

Tell your doctor if you are pregnant or plan to become pregnant. Having active ulcerative colitis or Crohn's disease symptoms during pregnancy may increase the risk of premature birth or low birth weight. The benefit of treating these conditions may outweigh any risks to the baby.

If you use Entyvio infusion or pen while you are pregnant, make sure any doctor caring for your new baby knows that you used the medicine during pregnancy. Being exposed to vedolizumab in the womb could affect your baby's vaccination schedule during the first few months of life.

If you are pregnant, your name may be listed on a pregnancy registry to track the effects of vedolizumab on the baby.

Breastfeeding

Tell your doctor if you are breastfeeding or plan to breastfeed. Entyvio passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take this medicine. 

How will I receive Entyvio?

Entyvio infusion is given into a vein in your arm for ulcerative colitis and Crohn's disease. Entyvio single-dose pre-filled pen is given under the skin (subcutaneously) as maintenance therapy for ulcerative colitis and Crohn's disease. Before you start treatment with Entyvio, your doctor may perform tests to make sure you do not have tuberculosis or other infections.

How is Entyvio infusion given? 

Entyvio infusion is given into a vein, usually once every 2 to 8 weeks. A healthcare provider will give you this infusion.

This medicine must be given slowly, and the infusion can take at least 30 minutes to complete.

You will be watched closely for a short time after receiving this medicine to make sure you do not have an allergic reaction.

It may take up to several weeks before your symptoms improve. Keep using the medication as directed, and tell your doctor if your symptoms do not improve after 14 weeks of treatment.

How is the Entyvio pen given?

Entyvio can be given subcutaneously (an injection under the skin) using the Entyvio Pen or prefilled syringe for maintenance treatment of UC or CD after at least 2 intravenous infusions.

See the detailed Instructions for Use that come with the Entyvio Pen or prefilled syringe about the right way to prepare and give this medicine.

Your healthcare provider will prescribe the type of device that is best for you. 

If your healthcare provider decides you or your caregiver can give your injections at home, you or your caregiver should be shown the right way to prepare the pen or prefilled syringe and inject this medicine. Do not inject this medicine until you or your caregiver has been shown the right way by your healthcare provider.

You may receive your first subcutaneous injection after at least 2 Entyvio infusions and in place of the next scheduled intravenous infusion.

You may receive Entyvio as an injection under your skin (subcutaneous) 1 time every 2 weeks.

Entyvio can be injected in your upper legs (thighs) or stomach area (abdomen). The upper arms may also be used if a caregiver gives the injection.

You should use a different injection site each time you use the medicine.

Do not give an injection into moles, scars, bruises, or skin that is tender, hard, red, or damaged.

Always check the label of your Entyvio pen or prefilled syringe to make sure you have the correct medicine before each injection.

Do not shake this medicine.

Entyvio dosing information

Usual Adult IV Entyvio Infusion Dose for Crohn's Disease or Ulcerative Colitis:

• 300 mg IV over 30 minutes at weeks 0, 2, and 6 and then every 8 weeks thereafter.

Usual Adult SC Entyvio Dose for Crohn's Disease or Ulcerative Colitis:

Following the first two Entyvio intravenous doses administered at Week 0 and Week 2, the dose may be switched to subcutaneous injection at Week 6.

• Week 6 and thereafter: Administer 108 mg subcutaneously once every 2 weeks.
• Discontinue therapy in patients who show no evidence of therapeutic benefit by Week 14.
• Entyvio may be switched from intravenous infusion to subcutaneous injection for patients in clinical response or remission beyond Week 6. To switch patients to subcutaneous injection, administer the first subcutaneous dose in place of the next scheduled intravenous infusion and every two weeks thereafter. 

Comments:

• Before starting therapy, patients should be brought up to date with all immunizations according to current immunization guidelines.
• Discontinue if no evidence of therapeutic benefit by Week 14.

Uses:

• Adult Ulcerative Colitis (UC): Adults with moderately to severely active ulcerative colitis. This drug is used for inducing and maintaining clinical response or remission, improving endoscopic appearance of the mucosa, or achieving corticosteroid-free remission.
• Adult Crohn's Disease (CD): Adults with moderately to severely active Crohn's Disease. This drug is used for achieving clinical response or remission, or achieving corticosteroid-free remission.

What happens if I miss a dose?

If you are not able to have your injection or infusion at your regular scheduled time or you miss a dose of Entyvio, inject the dose as soon as possible. Then, inject your next dose every 2 weeks thereafter. If you are not sure when you should have your next injection or infusion, call your healthcare provider. 

What happens if I overdose?

If you take more Entyvio than you were told to take, call your healthcare provider.

What should I avoid while receiving Entyvio?

Do not receive a "live" vaccine while using Entyvio, and avoid coming into contact with anyone who has recently received a live vaccine. There is a chance that the virus could be passed on to you. Live vaccines include measles, mumps, rubella (MMR), rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and nasal flu (influenza) vaccine.

You may receive "killed-virus" vaccines such as a flu shot, polio vaccine, rabies vaccine, or hepatitis A vaccine. Ask your doctor before receiving any vaccine while you are being treated with Entyvio.

Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.

What other drugs will affect Entyvio?

Tell your doctor about all your other medicines, especially:

• natalizumab;
• medicines to treat psoriasis or rheumatoid arthritis, such as etanercept or golimumab;
• other medicines to treat Crohn's disease or ulcerative colitis, such as adalimumab, certolizumab, infliximab; or
• other drugs that weaken the immune system such as cancer medicine, steroids, and medicines to prevent organ transplant rejection.

This list is not complete. Other drugs may interact with vedolizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Entyvio J code

Entyvio J code J3380 (1 mg injection).

J codes are used for medicines that are not taken orally and include injections, inhalations, and chemotherapies. J codes are important for accurate and consistent coding for billing and reimbursement purposes.

Your physician will need the Entyvio J-code when filling out forms for your treatment.

Ingredients

Active ingredient: vedolizumab 

Inactive ingredients: arginine hydrochloride, histidine, histidine monohydrochloride, polysorbate 80 and sucrose.

Storage

• Store in a refrigerator between 36°F to 46°F (2°C to 8°C).
• If needed, the prefilled syringe or prefilled pen can be left out of the refrigerator in its box at room temperature up to 77°F (25°C) for up to 7 days (for example, when traveling). 
• Do not use the prefilled syringe or prefilled pen if left out of the refrigerator for more than 7 days or left in direct sunlight.
• Do not freeze. 
• Do not use if it has been frozen. 
• Keep this medicine in the original package to protect from light until the time of use. 
• Entyvio Pen or prefilled syringe is not made with natural rubber latex. 
• Keep all medicines out of the reach of children. 

Company

 Entyvio is manufactured by Takeda Pharmaceuticals U.S.A., Inc. Lexington, MA 02421.

Entyvio Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There are 2 for Entyvio.

Popular FAQ

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer